Vertex rated at neutral by Merrill

Merrill Lynch analyst Hari Sambasivam rated Vertex Pharmaceuticals Inc. at neutral following the company's uneventful second quarter, including revenues of $29.7 million, expenses of $108.9 million and pro-forma loss per share of $0.71. The losses were higher than the analyst's estimates of $44.6 million, $107.2 million and $0.57 loss per share, respectively. Shares of the Cambridge, Mass.-based biotechnology company were down $2.18, or 6.13%, at $33.37 on volume of 1,958,336 shares versus the three-month running average of 1,650,560 shares. (Nasdaq: VRTX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.